CD8A and cancer: The combination of BRAFi and immunotherapy is gaining acceptance as a rational approach to cancer treatment, and is undergoing clinical investigation in melanoma [42], where BRAFi has been shown to evoke tumor CD8+ T cell infiltration in melanoma patient samples [33, 43] and in thyroid mouse model [35].